MX2015015681A - Pharmaceutical composition comprising fingolimod. - Google Patents

Pharmaceutical composition comprising fingolimod.

Info

Publication number
MX2015015681A
MX2015015681A MX2015015681A MX2015015681A MX2015015681A MX 2015015681 A MX2015015681 A MX 2015015681A MX 2015015681 A MX2015015681 A MX 2015015681A MX 2015015681 A MX2015015681 A MX 2015015681A MX 2015015681 A MX2015015681 A MX 2015015681A
Authority
MX
Mexico
Prior art keywords
fingolimod
pharmaceutical composition
capsules
lubricant
tablets
Prior art date
Application number
MX2015015681A
Other languages
Spanish (es)
Inventor
Fernández Lisardo Álvarez
Van Frans Dalen
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP2013059807 priority Critical
Application filed by Synthon Bv filed Critical Synthon Bv
Priority to PCT/EP2013/072767 priority patent/WO2013190151A1/en
Publication of MX2015015681A publication Critical patent/MX2015015681A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Abstract

The present invention relates to a pharmaceutical composition suitable for oral administration of fingolimod, which composition exhibits improved stability and has advantageous properties in making orally administrable final dosage forms such as capsules or tablets. The composition comprises fingolimod or a pharmaceutically acceptable salt or ester thereof, tripotassium citrate and, optionally, a lubricant.
MX2015015681A 2013-05-13 2013-10-31 Pharmaceutical composition comprising fingolimod. MX2015015681A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP2013059807 2013-05-13
PCT/EP2013/072767 WO2013190151A1 (en) 2013-05-13 2013-10-31 Pharmaceutical composition comprising fingolimod

Publications (1)

Publication Number Publication Date
MX2015015681A true MX2015015681A (en) 2016-03-15

Family

ID=49517499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015681A MX2015015681A (en) 2013-05-13 2013-10-31 Pharmaceutical composition comprising fingolimod.

Country Status (2)

Country Link
MX (1) MX2015015681A (en)
WO (1) WO2013190151A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101367574B1 (en) * 2003-04-08 2014-02-25 미쓰비시 타나베 파마 코퍼레이션 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod

Also Published As

Publication number Publication date
WO2013190151A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
BR112015020389A8 (en) carbazole compounds useful as bromodomain inhibitors, their use as well as pharmaceutical composition and product comprising them
EA201300989A1 (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF TAPENTADOL FOR Oral administration
EA201290982A1 (en) Pharmaceutical compositions, preventing abuse
EA032824B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
EA201200937A1 (en) Solid medicine form ticagrelor
MX2012005163A (en) Oral formulations of a hedgehog pathway inhibitor.
WO2010092090A3 (en) Novel salts of sitagliptin
CN104736526A (en) Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
MX2013013223A (en) Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2012010708A (en) Controlled release pharmaceutical compositions of tapentadol.
MY165149A (en) Use of binders for manufacturing storage stable formulations
EA201690102A1 (en) Pharmaceutical composition containing dimethylfumate for introduction to low daily dose
MX2011002065A (en) Micronised progesterone pharmaceutical composition and uses thereof.
SG11201803699YA (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
EP2661273A4 (en) Pharmaceutical compositions of iron for oral administration
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
EA201590449A1 (en) Oral prepared medicine composition
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
BR112013004440A2 (en) METHOD FOR PARENTERAL ADMINISTRATION OF A COMPOSITION, PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION, KIT and PHARMACEUTICAL SYSTEM FOR PARENTERAL ADMINISTRATION
BR112014008550A2 (en) rasagiline citramide
BR112015020453A2 (en) oral extended-release dosage forms of tofacitinib
MX2014006190A (en) Novel crystalline form of ticagrelor and process for the preparation thereof.
EA201290734A1 (en) Rifaximin in the form of powder, the method of its production and the composition of controlled liberation containing rifaximin indicated, useful for achieving a long-term effect
MX2015000151A (en) Heterocyclic modulators of lipid synthesis.